Hims & Hers Health Inc. (HIMS) saw its stock plunge over 20% in after-hours trading on Monday, despite reporting better-than-expected Q4 revenue. The telehealth company's earnings met analyst estimates, but its outlook for 2025 growth fell short of expectations, sparking investor concerns.

For Q4 2024, Hims & Hers reported earnings per share of $0.11, in line with analyst consensus estimates. Revenue came in at $481.14 million, beating expectations of $470.31 million and marking a 95% year-over-year increase. The company's subscriber base grew to 2.2 million, up 45% from the previous year.

However, the company's guidance for 2025 revenue and adjusted EBITDA disappointed Wall Street. Hims & Hers expects full-year 2025 revenue of $2.3 billion to $2.4 billion, representing growth of just 16% to 22% year-over-year, compared to analyst estimates of $2.5 billion. The company also forecasted adjusted EBITDA of $270 million to $320 million, reflecting a margin of 12% to 13%.